Aankondiging • 22h
Genetic Analysis AS to Report Q2, 2026 Results on Aug 28, 2026 Genetic Analysis AS announced that they will report Q2, 2026 results on Aug 28, 2026 Aankondiging • Jul 16
Genetic Analysis Publishes Peer-Reviewed Study Demonstrating Consistent Diagnostic Performance of Ga-Map Dysbiosis Test Across Geographically Diverse Populations Genetic Analysis AS announced the publication of a peer-reviewed study in the scientific journal Gut Microbes. The publication demonstrates that the GA-map Dysbiosis Test delivers consistent results across geographically diverse populations. These findings address one of the major challenges in microbiome diagnostics, population variability, and support the broader international applicability of the GA-map diagnostic platform. Demonstrating consistent diagnostic performance across different geographic regions is an important prerequisite for microbiome tests intended for widespread clinical use. The study, 'Towards Standardized Gut Microbiota Diagnostics: Normobiosis Beyond Geographical Borders,' evaluates the performance of the GA-map Dysbiosis Test across multiple international cohorts. Using its standardized, targeted marker panel and clinically validated interpretation algorithm, the test consistently classified microbiome status against a consistent healthy reference population across different geographic regions. These findings demonstrate how the GA-map approach reduces analytical variability while maintaining diagnostic performance, supporting its integration into routine clinical settings and larger healthcare systems. The study analysed more than 800 samples from multiple countries and showed that the Dysbiosis Index (DI), the core output of the test, remains stable across populations. Importantly, healthy individuals from different regions exhibited comparable DI profiles, with no systematic geographic bias in dysbiosis classification. Aankondiging • May 22
Genetic Analysis AS Announces Board and Committee Appointments Genetic Analysis AS, at the AGM held on 20 May 2026 elected Jonathan Kohn as Board member and elected following members for the nomination committee: Bjørn Fuglaas (Chair); Svein Lien and Kari Stenersen. Aankondiging • Apr 29
Genetic Analysis AS to Report Q1, 2026 Results on May 28, 2026 Genetic Analysis AS announced that they will report Q1, 2026 results on May 28, 2026 Aankondiging • Mar 13
Genetic Analysis AS Launches GA-Map Dysbiosis Test AInsight for AI-Assisted Interpretation Genetic Analysis AS announced the launch of GA-map Dysbiosis Test AInsight, an AI-assisted interpretation platform designed to translate microbiome analysis results into structured and clinically relevant insights, supporting broader adoption of microbiome testing in clinical practice. The GA-map Dysbiosis Test is a CE-marked molecular diagnostic assay designed to profile gut microbiome and evaluate intestinal dysbiosis by comparing a patient's microbiome profile to a healthy reference population. AInsight supports healthcare professionals by structuring microbiome findings and contextualizing deviations in bacterial abundance using curated scientific evidence. The platform utilizes an AI language model to retrieve clinically relevant associations linked to each bacterial marker measured by the GA-map Dysbiosis Test. By simplifying the interpretation of microbiome results, AInsight is expected to support the broader clinical use of the GA-map Dysbiosis Test and contribute to increased demand for GA's reagent kit products. Similar to the GA-map Dysbiosis Test, which operates within a predefined and clinically validated closed diagnostic system, the AI model deployed in AInsight is restricted to retrieving information exclusively from GA's Bacteria Compendium - GA's curated knowledge base. This controlled framework ensures that generated interpretation reports remain aligned with the validated scientific foundation underpinning the GA-map Dysbiosis Test. The addition of AInsight enables automated generation of structured interpretation reports for individual microbiome profiles and supports scalable report generation for laboratory workflows, enabling laboratories to efficiently handle increasing testing volumes. The reports generated by GA-map Dysbiosis Test AInsight are intended to provide informational support and should always be interpreted within the broader clinical context by qualified healthcare professionals. By lowering the barrier to interpreting microbiome test results, AInsight represents an important step in GA's strategy to expand the clinical use of its GA-map diagnostic platform. Aankondiging • Jan 27
Genetic Analysis AS to Report Fiscal Year 2025 Results on Feb 25, 2026 Genetic Analysis AS announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Feb 25, 2026 Aankondiging • Nov 17
Genetic Analysis AS Announces Completion of the Biomarker Panel Development in Its Ongoing IBD Precision Dx Project Genetic Analysis AS announced the completion of the biomarker panel development in its ongoing IBD Precision Dx project. This marks a major milestone in the project, with GA now progressing to the final validation phase and completion of the software development. The goal of the IBD Precision Dx project is to develop a microbiome-based diagnostic test capable of predicting disease course in Ulcerative Colitis (UC) patients, thereby supporting earlier and more targeted treatment decisions. The project is conducted in collaboration with two Scandinavian university hospitals, Akershus University Hospital (AHUS) and University hospital of Gothenburg (UGOT) and supported by funding of approximately EUR 2 million from the Research Council of Norway. GA has now finalized the bacteria biomarker panel design freeze, marking the completion of the assay development phase. The resulting biomarker panel enables analysis of the bacterial profile in stool samples to stratify UC patients according to predicted disease severity. Testing performed using this panel demonstrates strong technical results. GA has extensive experience in IBD research, having been actively involved in the field since 2013. Over the years, the company has built an extensive knowledge base, providing valuable insight that has played a key role in designing and conducting this IBD project, ultimately leading up to the development of the GA-map® IBD Precision Dx. The new assay will leverage GA's proprietary GA-map® technology platform for standardized, multiplex analysis adapted on the Luminex® xMAP® technology. This approach will enable commercialization of the assay on the Lumine xMAP® platform and make it available to laboratories and research users worldwide. Clinical need and market relevance: IBD affects approximately 5-6 million people across the US and Europe and imposes a significant burden on patients and healthcare systems, with annual healthcare costs estimated at EUR 12-13 billion2). Beyond healthcare costs, IBD has profound impacts on patients' quality of life, productivity, and social functioning. More than half of IBD patients are diagnosed with UC3). There is a recognized need for improved tools to support personalized treatment strategies and optimize therapy selection. Currently, no diagnostic tool exists to predict whether an UC patient will experience a mild or severe disease course. As a result, treatment optimization remains an unmet clinical need. Early administration of biologic therapy in high-risk patients is associated with better outcomes, underscoring the importance of early, precise disease course prediction. The GA-map®IBD Precision Dx test aims to fill this gap by enabling personalized treatment strategies and improved patient outcomes. Aankondiging • Oct 29
Genetic Analysis AS to Report Q3, 2025 Results on Nov 27, 2025 Genetic Analysis AS announced that they will report Q3, 2025 results on Nov 27, 2025 Aankondiging • Sep 24
Genetic Analysis AS Launches GA-map MHI GutHealth Reagent Kit Genetic Analysis AS announced the launch of a novel Research Use Only (RUO) reagent kit, the GA-map MHI GutHealth. The test provides an advanced tool for measuring antibiotic-induced microbiome imbalances and has been validated for recurrent Clostridioides difficile infection (rCDI). With this launch, GA-map MHI Gut Health is made available for Luminex xMAP users globally. As communicated on December 20, 2024, GA and Ferring Pharmaceuticals announced a collaboration to develop a new microbiome diagnostic test. Since then, GA has brought together two established technologies - GA's PCR-based microbiome diagnostic platform (GA-map®?1) and Ferring's research-validated biomarker for measuring post-antibiotic microbiome imbalances (the 'Microbiome Health Index(TM)'2). The test utilizes the unique Luminex xMAP®? technology for targeted and effective multiplex analysis, making it readily accessible for LuminexxMAP users worldwide. Initially, GA-map®? MHI GutHealth is targeted towards rCDI patients, providing clinicians with a rapid tool to assess baseline microbiome imbalances and monitor treatment effects during microbiome restoration. The test also has potential as a pharmacodynamic (PD) measure of microbiota restoration in clinical trials for Live Biotherapeutic Products (LBPs), Fecal Microbiota Transplants (FMTs), and other microbiome restoration approaches. This is relevant in all clinical trials where antibiotic-associated microbiome imbalances play a critical role, such as Graft-versus-Host Disease (GvHD), infectious diseases, immunocompromised patients, and MDRO-colonized patients3. With the launch of the GA-map®?MHI GutHealth test, GA expands into a novel diagnostic field. The market potential for a diagnostic test aiding treatment and follow-up of rCDI is significant, with close to 500,000 annual CDI cases in the US alone4. Thus, the test will contribute to Genetic Analysis' commercial activities and provide incremental contribution to the Company's revenue base. Aankondiging • Jul 31
Genetic Analysis AS and Pangea Laboratory LLC Announces the Launch of GA-Map MHI GutHealth in the USA Genetic Analysis AS and Pangea Laboratory LLC announced the launch of the GA-map MHI GutHealth as a Research Use Only (RUO) test in the USA. As part of the collaboration Pangea will perform analysis in their CLIA-certified, CAP-accredited laboratory in Tustin, California. The GA-map MH I GutHealth is the first microbiome-based diagnostic test providing clinically actionable insights into antibiotic-induced microbiome imbalances. The test has been developed by GA in collaboration with Ferring Pharmaceuticals and combines GA's proprietary GA-map technology with Ferring's Microbiome Health Index(TM). MHI is a validated biomarker measuring the ratio of pro-inflammatory versus anti-inflammatory bacteria in the patient's gut, demonstrated in recurrent Clostridioides difficile (rCDI) infected patients. Initially the test will be targeted towards patients with rCDI, providing clinicians with a rapid tool for baseline microbiome imbalance assessment and for monitoring the effect during microbiome restoration treatment. rCDI infection impacts approximately 500,000 patients annually in the United States, and up to 35% of initial CDI cases will experience a recurrence, which is associated with up to 30,000 deaths annually. Beyond rCDI, the test has the potential to support clinical decision-making in patient groups where antibiotic-associated microbiome imbalance plays a critical role.raft-versus-Host Disease (GvHD), infectious diseases, immunocompromised patients and patients colonized with multidrug-resistant organisms. The test will now be available for analysis at Pangea. As part of the collaboration, GA will supply reagent kits to Pangea. The agreement outlines an ongoing partnership without predefined order volumes or minimum delivery commitments. Revenues for GA will be generated based on the number of tests sold. GA is not obliged to make any additional financial investments as part of the collaboration. Aankondiging • Jul 28
Genetic Analysis AS to Report Q2, 2025 Results on Aug 27, 2025 Genetic Analysis AS announced that they will report Q2, 2025 results on Aug 27, 2025 New Risk • Jun 27
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (26% average weekly change). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Market cap is less than US$10m (kr60.8m market cap, or US$6.02m). Minor Risk Revenue is less than US$5m (kr20m revenue, or US$2.0m). Aankondiging • Jun 17
Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 4.139347 million. Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 4.139347 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 4,813,194
Price\Range: NOK 0.86
Transaction Features: Rights Offering Reported Earnings • May 28
First quarter 2025 earnings released: kr0.093 loss per share (vs kr0.14 loss in 1Q 2024) First quarter 2025 results: kr0.093 loss per share (improved from kr0.14 loss in 1Q 2024). Revenue: kr4.02m (down 16% from 1Q 2024). Net loss: kr4.59m (loss narrowed 21% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. Aankondiging • May 28
Genetic Analysis AS has filed a Follow-on Equity Offering in the amount of SEK 7.1 million. Genetic Analysis AS has filed a Follow-on Equity Offering in the amount of SEK 7.1 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 8,255,814
Price\Range: SEK 0.86
Transaction Features: Rights Offering Aankondiging • May 06
Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 12.805035 million. Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 12.805035 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 14,889,576
Price\Range: NOK 0.86
Transaction Features: Subsequent Direct Listing Aankondiging • May 05
Genetic Analysis as Announces Stepping Down of Jethro Holter as Current Chairman Genetic Analysis AS announced that Dr. Jethro Holter, the current Chairman, to step down from his role and not seek re-election. Dr. Holter will be focusing on his new position as CEO of AdjuTec Pharma. Aankondiging • Apr 28
Genetic Analysis AS to Report Q1, 2025 Results on May 27, 2025 Genetic Analysis AS announced that they will report Q1, 2025 results on May 27, 2025 Aankondiging • Apr 22
Genetic Analysis AS and Thalys Medical Technology Group Announce the Launch of A Microbiome Test to the Chinese Consumer Health Market Genetic Analysis AS ("GA") and Thalys Medical Technology Group Corporation ("Thalys") announced the launch of a microbiome test for the Consumer Health (D2C) market in China. The test is based on GA's clinically validated microbiome test, the GA-map® Dysbiosis Test, but specifically adapted to suit the Chinese market. This strategic cooperation represents the launch of GA's commercial presence in the fast-growing market Chinese market via its partner Thalys and their new Independent Clinical Lab (ICL) in Shanghai. The Chinese D2C microbiome testing market is growing rapidly. The estimated market size in 2023 was ~USD50-80 million, and with a projected CAGR of 20-30%, it has an expected 2030 Market Size of USD200-300 million. Main growth drivers include increased consumer interest in gut health, probiotics and personalized nutrition, as well as advances in e-commerce & digital health platforms such as Tmall and WeChat. The Thalys microbiome testing service powered by the GA-map® Dysbiosis Test will provide consumers in China with a fast and affordable test. Thalys has developed a D2C mobile software where customers can easily subscribe, pay and view report results on their mobile phones. The results will offer insights into the beneficial and potentially harmful microbes present in the gut, along with potential health- and wellness implications. Test results will include personalized probiotics recommendations as well as weight management & metabolic health insights. The upcoming launch of the GA-map® Dysbiosis Test to the Chinese Consumer Health market marks the completion of the first stage of the Thalys and GA collaboration. Moving forward, the Thalys Group will further develop and distribute tests based on GA's GA-map® Technology in China. Within the framework of the cooperation, GA will supply reagent kits to Thalys. Thalys has invested in the clinical study activities associated with the project and developing front-end consumer software solutions, whereas GA has contributed its proprietary software and algorithm development from internal resources. The agreement set out for the cooperation is structured as an ongoing partnership without predefined order volumes or minimum delivery commitments, but revenues will be generated for GA based on the number of tests sold. GA is not obliged to make any additional financial investments as part of the collaboration. Reported Earnings • Feb 27
Full year 2024 earnings released: kr0.30 loss per share (vs kr0.62 loss in FY 2023) Full year 2024 results: kr0.30 loss per share (improved from kr0.62 loss in FY 2023). Revenue: kr20.7m (down 11% from FY 2023). Net loss: kr14.8m (loss narrowed 38% from FY 2023). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Aankondiging • Jan 28
Genetic Analysis AS to Report Fiscal Year 2024 Results on Feb 26, 2025 Genetic Analysis AS announced that they will report fiscal year 2024 results on Feb 26, 2025 New Risk • Nov 21
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr17m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 3.4% per year over the past 5 years. Market cap is less than US$10m (kr20.2m market cap, or US$1.83m). Minor Risks Shareholders have been diluted in the past year (29% increase in shares outstanding). Revenue is less than US$5m (kr20m revenue, or US$1.8m). Reported Earnings • Nov 17
Third quarter 2024 earnings released: kr0.065 loss per share (vs kr0.17 loss in 3Q 2023) Third quarter 2024 results: kr0.065 loss per share (improved from kr0.17 loss in 3Q 2023). Revenue: kr3.62m (down 24% from 3Q 2023). Net loss: kr3.23m (loss narrowed 25% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. Aankondiging • Oct 17
Genetic Analysis AS to Report Q3, 2024 Results on Nov 15, 2024 Genetic Analysis AS announced that they will report Q3, 2024 results on Nov 15, 2024 Aankondiging • Aug 01
Genetic Analysis AS to Report Q2, 2024 Results on Aug 30, 2024 Genetic Analysis AS announced that they will report Q2, 2024 results on Aug 30, 2024 Aankondiging • Jun 09
Genetic Analysis as Announces Resignation of Eilert Aamodt as Chief Financial Officer Microbiome DX company Genetic Analysis AS announced that Eilert Aamodt has decided to resign as CFO to take on a new position in another company and industry. He will remain in his current role until the end of August 2024, ensuring a smooth and efficient transition for GA. Aamodt has been with GA since February 2021, and GA has initiated a process to recruit his replacement. Reported Earnings • May 30
First quarter 2024 earnings released: kr0.14 loss per share (vs kr0.29 loss in 1Q 2023) First quarter 2024 results: kr0.14 loss per share (improved from kr0.29 loss in 1Q 2023). Revenue: kr4.77m (down 25% from 1Q 2023). Net loss: kr5.80m (loss narrowed 21% from 1Q 2023). Aankondiging • May 01
Genetic Analysis AS to Report Q1, 2024 Results on May 29, 2024 Genetic Analysis AS announced that they will report Q1, 2024 results on May 29, 2024 Reported Earnings • Apr 22
Full year 2023 earnings released: kr0.62 loss per share (vs kr1.13 loss in FY 2022) Full year 2023 results: kr0.62 loss per share (improved from kr1.13 loss in FY 2022). Revenue: kr23.2m (up 12% from FY 2022). Net loss: kr23.8m (loss narrowed 16% from FY 2022). Aankondiging • Apr 16
Genetic Analysis AS, Annual General Meeting, May 14, 2024 Genetic Analysis AS, Annual General Meeting, May 14, 2024. New Risk • Mar 26
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 8.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (69% increase in shares outstanding). Market cap is less than US$10m (kr24.9m market cap, or US$2.31m). Minor Risk Revenue is less than US$5m (kr23m revenue, or US$2.2m). Reported Earnings • Mar 01
Full year 2023 earnings released: kr0.62 loss per share (vs kr1.13 loss in FY 2022) Full year 2023 results: kr0.62 loss per share (improved from kr1.13 loss in FY 2022). Revenue: kr23.2m (up 12% from FY 2022). Net loss: kr23.8m (loss narrowed 16% from FY 2022). Aankondiging • Jan 31
Genetic Analysis AS to Report Fiscal Year 2023 Results on Feb 29, 2024 Genetic Analysis AS announced that they will report fiscal year 2023 results on Feb 29, 2024 Aankondiging • Dec 23
Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 3.235125 million. Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 3.235125 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 4,095,095
Price\Range: NOK 0.79
Transaction Features: Rights Offering New Risk • Nov 12
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 9.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (kr35.5m market cap, or US$3.20m). Minor Risk Revenue is less than US$5m (kr22m revenue, or US$2.0m). New Risk • Nov 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 9.8% per year over the past 5 years. Market cap is less than US$10m (kr22.2m market cap, or US$2.01m). Minor Risk Revenue is less than US$5m (kr22m revenue, or US$2.0m). Aankondiging • Nov 05
Genetic Analysis AS Provides Earnings Guidance for the Year 2023, 2024, and 2025 Genetic Analysis AS provided earnings guidance for the year 2023, 2024, and 2025. For 2023, the company expects Operating income of approximately NOK 20 million- NOK 25 million.For 2024, the company expects Operating income of approximately NOK 25 million - NOK 35 million.For 2025, the company expects Operating income of approximately NOK 40 million -NOK 60 million as well as positive cash flow. Aankondiging • Nov 04
Genetic Analysis AS has filed a Follow-on Equity Offering in the amount of NOK 9 million. Genetic Analysis AS has filed a Follow-on Equity Offering in the amount of NOK 9 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 11,392,405
Price\Range: NOK 0.79
Transaction Features: Rights Offering Reported Earnings • Nov 04
Third quarter 2023 earnings released: kr0.17 loss per share (vs kr0.27 loss in 3Q 2022) Third quarter 2023 results: kr0.17 loss per share (improved from kr0.27 loss in 3Q 2022). Revenue: kr4.73m (flat on 3Q 2022). Net loss: kr4.32m (loss narrowed 35% from 3Q 2022). Aankondiging • Nov 03
Genetic Analysis AS Announces Resignation of Staffan Strömberg from the Board of Directors Genetic Analysis AS announced that the board member Staffan Strömberg has resigned from the Board of Directors ("BoD") at his request, due to high workload, with immediate effect. Aankondiging • Oct 24
Genetic Analysis AS Launches the GA-map® Discovery - New Microbiome Profiling Service Offering Directed to Research Customers in the Academia and Microbiome Industry Genetic Analysis AS announced that the Company launches the GA-map® Discovery - a new microbiome profiling service offering directed to research customers in the academia and microbiome industry. The GA-map® Discovery is GA's first dedicated offering in the research market which is currently witnessing considerable growth - cementing GA's position as a pioneer in microbiome disease diagnostics. Built on the standardized GA-map® platform, GA-map® Discovery is a comprehensive end-to-end microbiota research service for gut and oral microbiota profiling. Comprising more than 170 bacteria markers, the GA-map® Discovery was developed to facilitate the discovery of new biomarkers and bacteria signatures associated with health and disease. GA-map® Discovery is a perfect choice for comparative studies of different disease cohorts, treatment responses, and more. The launch of GA-map ® Discovery brings to the market a research service with high accuracy, exceptional reproducibility, and short turnaround time, enabling cost-effective microbiota measurements. The GA-map® Discovery is GA's first dedicated offering in the research market. In recent years, microbiome research has witnessed considerable growth, fuelling new inventions in disease diagnostics, treatment selection and monitoring, and disease prevention. The research market for microbiome measurement was valued at $859 million in 2021 and is projected to reach $3,417 million by 2031. Aankondiging • Oct 18
Genetic Analysis AS to Report Nine Months, 2023 Results on Nov 16, 2023 Genetic Analysis AS announced that they will report nine months, 2023 results on Nov 16, 2023 New Risk • Oct 12
New major risk - Revenue and earnings growth Earnings have declined by 12% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr20m free cash flow). Earnings have declined by 12% per year over the past 5 years. Market cap is less than US$10m (kr26.9m market cap, or US$2.46m). Minor Risks Share price has been volatile over the past 3 months (9.1% average weekly change). Revenue is less than US$5m (kr22m revenue, or US$2.1m). Reported Earnings • Sep 01
Second quarter 2023 earnings released: kr0.22 loss per share (vs kr0.24 loss in 2Q 2022) Second quarter 2023 results: kr0.22 loss per share (improved from kr0.24 loss in 2Q 2022). Revenue: kr5.70m (up 4.0% from 2Q 2022). Net loss: kr5.49m (loss narrowed 9.4% from 2Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in Sweden. Aankondiging • Aug 01
Genetic Analysis AS to Report Q2, 2023 Results on Aug 30, 2023 Genetic Analysis AS announced that they will report Q2, 2023 results on Aug 30, 2023 Aankondiging • May 12
Genetic Analysis AS Announces Changes in Members of Nomination Committee Genetic Analysis AS held its Annual General Meeting on May 11, 2023 approved Svein Lien and Eilert Aamodt were elected as members of nomination committee. Breakeven Date Change • Apr 25
Forecast breakeven date pushed back to 2025 The analyst covering Genetic Analysis previously expected the company to break even in 2024. New forecast suggests losses will reduce by 58% per year to 2024. The company is expected to make a profit of kr4.00m in 2025. Average annual earnings growth of 66% is required to achieve expected profit on schedule. Major Estimate Revision • Mar 14
Consensus revenue estimates fall by 12% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from kr34.0m to kr30.0m. Forecast losses increased from -kr0.59 to -kr0.68 per share. Biotechs industry in Sweden expected to see average net income decline 10% next year. Consensus price target of kr3.50 unchanged from last update. Share price was steady at kr1.68 over the past week. Breakeven Date Change • Mar 13
Forecast breakeven date pushed back to 2025 The analyst covering Genetic Analysis previously expected the company to break even in 2024. New forecast suggests losses will reduce by 58% per year to 2024. The company is expected to make a profit of kr4.00m in 2025. Average annual earnings growth of 66% is required to achieve expected profit on schedule. Reported Earnings • Feb 19
Full year 2022 earnings: EPS in line with expectations, revenues disappoint Full year 2022 results: kr1.14 loss per share (improved from kr1.16 loss in FY 2021). Revenue: kr20.7m (up 55% from FY 2021). Net loss: kr28.3m (loss narrowed 2.5% from FY 2021). Revenue missed analyst estimates by 20%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Sweden. Aankondiging • Jan 31
Genetic Analysis AS Announces Executive Changes Genetic Analysis AS announce that GA is strengthening and future-proofing the organization within business development, sales, andproduct development to be better positioned to harvest opportunities in the microbiome market. As diagnostics is now becoming a vital part of the treatment regime for gastroenterological disorders, GA believes that the microbiome diagnostic market will continue to rapidly increase in the coming years. Following the recent regulatory approval of microbiome-altering drugs in the US, GA also sees a significant increase in opportunitiesto add several new markers on the GA-map® platform. GA announce that GA's Chief Technology Officer Kari Furu has accepted the new position as Head of Business and Product Development. Kari and GA's development teams have developed innovative products for GA, and its product development within IBD attracted strong interest recently as a finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD. GA announce that Ms. Pranvera Hiseni has accepted the position of Development Manager, reporting to the Head of Business and Product Development, where she will be responsible for GA's development projects. Pranvera has worked in GA's development department with a key focus on platform development and has also been instrumental in building up the HumGut Database, a comprehensive human gut metagenome collection. After the implementation of the new organization, the management team will consist of: Ronny Hermansen (CEO); Eilert Aamodt (CFO); Cristina Casén (Senior VP Clinical & Medical Affairs); Lars Tiller (Head of Operations); Kari Furu (Head of Business and Product Development); Detlef Janke (Commercial Director). With these new organizational changes, the previous responsibilities of the CTO and CCO will be implemented under the Product and Software development team and the clinical team. The new organization will be implemented immediately. Aankondiging • Jan 20
Genetic Analysis as Achieves Thai Fda License for Ga-Map[®] Dysbiosis Test in Thailand Genetic Analysis AS ("GA") announced that Thailand Food and Drug Administration ("Thai FDA") authority have granted GA license for the GA-map® Dysbiosis Test in Thailand. GA has, in cooperation with its distributor Hausen Bernstein Co. Ltd. ("HB") filed for regulatory approval of the GA-map® Dysbiosis Test in 2022, and announce that the test has now been approved by the Thai FDA authorities for Clinical use in IBS and IBD patients. HB plans to launch the GA-map from their molecular lab in Bangkok and market the GA-map® products in wider Thailand. The market demand for gut microbiome assessments is rapidly increasing globally in private healthcare services, medical clinics, and academic research with a focus on identifying and categorizing the patient's microbiota. Together with HB, GA can now offer its Thai FDA-approved standardised gut microbiome testing platform to the Thai market to meet the growing interest and raise awareness of dysbiosis. Aankondiging • Jan 19
Genetic Analysis AS to Report Fiscal Year 2022 Results on Feb 17, 2023 Genetic Analysis AS announced that they will report fiscal year 2022 results on Feb 17, 2023 Board Change • Nov 16
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 8 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Anne Camilla Bondesson is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Reported Earnings • Nov 06
Third quarter 2022 earnings released: kr0.27 loss per share (vs kr0.28 loss in 3Q 2021) Third quarter 2022 results: kr0.27 loss per share (improved from kr0.28 loss in 3Q 2021). Revenue: kr4.77m (up 106% from 3Q 2021). Net loss: kr6.68m (loss narrowed 2.3% from 3Q 2021). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in Sweden. Reported Earnings • Aug 20
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: kr5.48m (up 177% from 2Q 2021). Net loss: kr6.06m (loss narrowed 12% from 2Q 2021). Over the next year, revenue is forecast to grow 62%, compared to a 215% growth forecast for the Biotechs industry in Sweden. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Chairperson Kathryn Baker was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 20
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: kr1.16 loss per share (up from kr1.29 loss in FY 2020). Revenue: kr13.4m (up 78% from FY 2020). Net loss: kr29.0m (loss widened 31% from FY 2020). Revenue was in line with analyst estimates. 
